To obtain a molecular definition of regulatory T (Treg) cell identity, we performed proteomics and transcriptomics on various populations of human regulatory and conventional CD4 + T (Tconv) cells. A protein expression signature was identified that defines all Treg cells, and another signature that defines effector Treg cells. These signatures could not be extrapolated from transcriptome data. Unique cellbiological and metabolic features in Treg cells were defined, as well as specific adaptations in cytokine, TCR, and costimulatory receptor signaling pathways. One such adaptation-selective STAT4 deficiency-prevented destabilization of Treg cell identity and function by inflammatory cytokines, while these signals could still induce critical transcription factors and homing receptors via other pathways. Furthermore, our study revealed surface markers that identify FOXP3 + CD4 + T cells with distinct functional properties. Our findings suggest that adaptation in signaling pathways protect Treg cell identity and present a resource for further research into Treg cell biology.
In Brief
Using high-resolution mass spectrometry and transcriptomics, Cuadrado et al. provide a molecular characterization of regulatory and conventional CD4 + T cell subsets, yielding markers to distinguish cells with different properties and insights into mechanisms that prevent regulatory T cells from exhibiting undesirable functional activities of the related but functionally antithetical conventional T cells.
SUMMARY
To obtain a molecular definition of regulatory T (Treg) cell identity, we performed proteomics and transcriptomics on various populations of human regulatory and conventional CD4 + T (Tconv) cells. A protein expression signature was identified that defines all Treg cells, and another signature that defines effector Treg cells. These signatures could not be extrapolated from transcriptome data. Unique cellbiological and metabolic features in Treg cells were defined, as well as specific adaptations in cytokine, TCR, and costimulatory receptor signaling pathways. One such adaptation-selective STAT4 deficiency-prevented destabilization of Treg cell identity and function by inflammatory cytokines, while these signals could still induce critical transcription factors and homing receptors via other pathways. Furthermore, our study revealed surface markers that identify FOXP3 + CD4 + T cells with distinct functional properties. Our findings suggest that adaptation in signaling pathways protect Treg cell identity and present a resource for further research into Treg cell biology.
INTRODUCTION

Treg cells constitute a distinct CD4
+ T cell lineage, defined by expression of the transcription factor FOXP3 and the ability to suppress immune responses (Josefowicz et al., 2012) . Treg cells safeguard immune tolerance, limit immune-cell-inflicted tissue damage, and promote tissue repair (Arpaia et al., 2015; Nosbaum et al., 2016) . Treg cells impede immunity against cancer (Nishikawa and Sakaguchi, 2014 ) and insufficient Treg cell function may underlie human autoimmune diseases and allergy (Pellerin et al., 2014) . Targeted strategies are therefore needed to boost or inhibit Treg cell function in human disease. For selective manipulation of the closely related Treg or Tconv cells, we need a detailed understanding of their distinctions at the molecular level. Treg cells generally do not produce cytokines such as IL-2, IL-4, IL-17, and IFN-g (here referred to as ''effector cytokines''), even when exposed to inflammatory cytokines (Josefowicz et al., 2012; Miyao et al., 2012; Rubtsov et al., 2010) . Treg cells do, however, respond to inflammatory cues, which can enhance suppressive function and induce expression of Th-cell-lineage-specific transcription factors and homing receptors (Josefowicz et al., 2012; Tan et al., 2016; Yu et al., 2015) . Under conditions that are not understood, inflammation may paradoxically also destabilize Treg cells, provoking production of effector cytokines Gao et al., 2015; van Loosdregt et al., 2013) . In cancer, the presence of Treg cells that produce effector cytokines marks a relatively favorable prognosis (Overacre-Delgoffe et al., 2017; Saito et al., 2016) . In autoimmune diseases, such Treg cells may, however, contribute to development of pathology (Pandiyan and Zhu, 2015) . Understanding the mechanisms that generally prevent production of effector cytokines by Treg cells and identification of markers that discriminate between Treg cells with and without the capacity to produce effector cytokines is important for diagnostic and therapeutic purposes.
How Treg cells normally resist acquisition of Tconv cell properties is incompletely understood. FOXP3 can directly suppress effector cytokine-encoding genes and prevent their expression through physical interaction with other transcription factors (Kwon et al., 2017; Li and Zheng, 2015; Li et al., 2014; Rudra et al., 2012) . Expression of Tconv cell-specific genes is furthermore opposed by an epigenetic layer of regulation (Ohkura et al., 2012) .
Here, we aimed to define human Treg cell identity at the molecular level through label-free quantitative proteomics and transcriptomics. We specifically examined blood-derived naive (n) and effector (e) Treg cells that, according to studies in mouse models (Siegmund et al., 2005; Smigiel et al., 2014) , respectively inhibit spurious priming of nTconv cells in lymphoid tissue and effector functions of T cells in non-lymphoid tissue. We furthermore analyzed an incompletely defined CD4 + T cell population, similar to ''fraction (Fr.) III'' (Miyara et al., 2009) , that produces effector cytokines, despite expressing FOXP3. Finally, we determined protein expression patterns in Treg cells cultured in vitro, with and without T cell receptor (TCR) stimulation. These analyses identified markers for the discrimination of functionally distinct FOXP3
+ CD4 + T cell types in human blood and defined a common Treg cell signature, and one specific to eTreg cells. The signatures showed that signaling pathways that control effector cytokine genes in Tconv cells are desensitized at strategic points in Treg cell activation. Low expression of, for example, STAT4, enabled Treg cells to respond to inflammatory cytokines without compromising Treg cell identity. Our findings provide insight into mechanisms protecting Treg cell identity in an inflammatory environment and present a resource for the further study of human Treg cell biology. Figures 1A and S1A ). Both Treg cell populations expressed FOXP3 and Helios and lacked IL-7 receptor a chain (CD127), while nTconv and mTconv cell populations conversely lacked FOXP3 and Helios, but did express CD127 (Figures S1B and S1C). We also isolated a CD45RA
RESULTS
Protein Expression Signatures Define Treg Cell
+ T cell population, similar to the previously described Fraction (Fr).III (Miyara et al., 2009 ), which contains cells that produce effector cytokines, despite expressing FOXP3 ( Figure S1B ). As originally defined, ''Fr.III'' was heterogeneous in expression of FOXP3, Helios, and CD127 (Figures S1B and S1C) and therefore likely included activated Tconv cells. Unlike nTconv and mTconv cells, both Treg cell populations were demethylated at the Treg cell-specific demethylated region (TSDR) in the FOXP3 gene locus ( Figure S1D ; Polansky et al., 2008) . Methylation of the TSDR in Fr.III cells was intermediate, likely reflecting the mixed composition of this cell population. Using high-resolution mass spectrometry (MS), we identified an average of 35,744 ± 3,757 peptides corresponding to 5,955 ± 344 protein groups in these samples. In total, 4,358 distinct proteins were quantified in all five CD4 + T cell subsets.
Of these, 422 proteins exhibited differential expression (FDR < 0.05) among the CD4 + T cell subsets, based on their label-free quantification (LFQ) values. Principal component analysis (PCA, Figure 1B ) and Pearson correlation ( Figure 1C ) of the total datasets and unsupervised hierarchical clustering of the differentially expressed proteins ( Figure 1D and Table S1 ) confirmed the close relatedness of biological replicates. Furthermore, these analyses separated the CD4 + T cell subsets primarily on basis of CD45RA expression, rather than by lineage ( Figure 1D ). Enrichment analysis revealed that naive Treg and Tconv cells shared high expression of proteins involved in processes such as pentose phosphate metabolism, NADP metabolism, and chromatin organization ( Figure 1D , clusters 7-8 and Table S1 ), while eTreg and mTconv cells shared high expression of proteins involved in protein synthesis, cell trafficking, signaling, and apoptosis ( Figure 1D , clusters 3-4 and Table  S1 ). The similarity in protein expression based on differentiation stage rather than lineage may in part reflect preferential localization in lymphoid tissue (naive cells) versus non-lymphoid tissue (effector cells) (Campbell, 2015; Smigiel et al., 2014) .
Despite their markedly different proteomes, nTreg and eTreg cells uniquely shared high (cluster 1) and low (cluster 9-10) expression of certain proteins that thus defined a common Treg cell protein signature. No signature uniquely defined nTreg cells. However, eTreg cells uniquely exhibited high expression of proteins in cluster 2 and low expression of proteins in cluster 6 (Table S1) , which thus defined an eTreg cell protein signature.
mRNA Expression Signatures Define Treg Cell Populations
The proteomic Treg cell signatures defined overlapped little with published transcriptomic signatures of similar cell populations (Miyara et al., 2009; Ferraro et al., 2014; Schmidl et al., 2014) . To allow direct comparison, we performed genome-wide mRNA deep sequencing of the five CD4 + T cell subsets. Also based on their transcriptome, nTreg and nTconv cells clustered together and away from the three effector and memory phenotype CD4 + T cell populations ( Figure 2A ). A total of 649 mRNAs (p < 0.05) was differentially expressed between the five CD4 + T cell subsets (Figure 2B and Table S2 ), including expected hallmark genes such as IL-7R, IKZF2 (HELIOS), and effector cytokines ( Figure S2A ). This analysis yielded an eTreg cell-specific ( Figure 2B , cluster 7; Table S2 ) and a common Treg cell mRNA signature (Figures 2B and 2C, cluster 6 ) that featured expected molecules such as FOXP3, IL2RA, TIGIT, and others. Indeed, this common Treg cell mRNA signature overlapped strongly with published signatures (Miyara et al., 2009; Schmidl et al., 2014) , especially with the one reported by Miyara et al. (2009) whose cell populations were closest to the ones studied here (Figure 2E and S2B) . In sharp contrast, only three molecules (FOXP3, SHMT2, and SWAP70) overlapped between our own proteomic and transcriptomic core Treg cell signatures ( Figure 2F ). The discordance between mRNA and protein was not specific for the Treg cell signature. In fact, of the 553 mRNAs and the 409 proteins that were significantly differentially expressed between the five CD4 + T cell subsets and could be quantified at both levels, only 48 overlapped (Figures 2G and S2C) . Direct measurement of proteins can therefore yield markedly different results than measurement of mRNAs (at least in cells analyzed at steady state), as is often found in these types of studies (Vogel and Marcotte, 2012) .
Protein Signatures Differ from mRNA Signatures
To quantitatively compare protein and mRNA levels, protein data were analyzed using intensity-based absolute quantification (iBAQ; Schwanh€ ausser et al., 2011) . Protein and mRNA abundance spanned more than five orders of magnitude (Figures 3A and 3D) . Most abundant were ribosomal and metabolic proteins ( Figure 3B and Table S3 ). The most abundant mRNAs encoded ribosome components and molecules involved in (immune) cell signaling and function ( Figure 3E and Table S3 ). Differentially expressed proteins, but not mRNAs, were generally more abundant ( Figures 3C and 3F) .
Expression levels of all 4,792 mRNA-protein pairs from our datasets, that could be mapped at both the transcriptome and proteome level, had a correlation coefficient of approximately 0.44 ± 0.01 ( Figure S3 ), similar to the values described for other human cells (Wilhelm et al., 2014) . Among the 422 differentially expressed proteins, 409 were detected at both mRNA and protein level and could be quantitatively compared ( Figure 3G ). Protein and mRNA expression levels generally correlated (e.g., FOXP3, IKZF2). However, the difference in expression was often sufficiently large only for one of the two (mRNA or protein) to reach the statistical cut off, explaining the limited overlap between the differentially expressed proteins and mRNAs ( Figure 2F ). Other studies commonly report such discrepancies between transcriptome and proteome data (Vogel and Marcotte, 2012) , especially for cells in steady state. This likely reflects differences in stability between mRNA and protein (Jovanovic et al., 2015) . These differences are likely less pronounced in cycling cells that have a greater need to synthesize proteins. Indeed, the most proliferative cell types in our analysis (Fr.III and eTreg cells) Table S1 ). Data are from three independent experiments, each with technical triplicate samples.
contained the lowest number of molecules differentially regulated at the protein level only ( Figure 3H ). Some molecules were truly differentially expressed at the mRNA or protein level only ( Figure 3H ), suggesting specific layers of regulation. For example, protein but not mRNA abundance was high in both nTreg and eTreg cells for FTH1 (Figure 3G) , a protein known to be under stringent translational control (Hentze et al., 2010 abundant in mTconv cells, despite low mRNA levels ( Figure 3G ). On the other hand, it was highly expressed at the mRNA but not at the protein level in both nTreg and eTreg cells ( Figure 3G ), explaining why it was in the common Treg cell transcriptome but not proteome signature. Combined proteome and transcriptome analysis reinforces confidence in pathway analyses. Such combined data strongly argued for example that the nuclear factor kB (NF-kB) and JAK-STAT pathways are desensitized in eTreg cells as compared to the other CD4 + T cell subsets ( Figure 3I ). Together, our findings underscore the importance of proteomic analysis for the functional characterization of cell types. S4F ; Rieckmann et al., 2017) . The common Treg cell signature included FOXP3 and IKZF2 (Helios), metabolic proteins GK, UGP2, and SHMT2, iron storage proteins Ferritin heavy and light chains (FTH1, FLT), as well as lysosomal proteins ASAH1, GGH, GUSB, SGSH, and PLBD2 that were all expressed at high abundance in Treg compared to Tconv cells ( Figures 4A and 4B ). The signature also included the glycolytic enzymes HK1 and ME2, the fatty acid oxidation enzyme APOO, and the mitochondrial fatty acid transporter (CPT1A), all expressed at low abundance in Treg compared to Tconv cells.
A number of signaling molecules was prominent in the common Treg cell signature. High expression of the deubiquitinase OTULIN, an inhibitor of TNFa-induced NF-kB activation (Keusekotten et al., 2013) and low expression of TNFRSF1A adaptor TRADD (Figures 4A and 4B) , together with high expression of TNFRSF1B at the mRNA level (Table S2 ), suggest that Treg cells exhibit adaptations in TNFR signaling. The signature also suggests adaptation of the PI3K/AKT/mTOR pathway ( Figures 4A and 4B) , with high expression of the lipid phosphatase INPP5D (SHIP-1), that inhibits PI3K-AKT signaling (Liu et al., 1999) , and low expression of the mTOR activators RPS6KA1 and RPS6KA3. Finally, the low expression of STAT4 and NFATc2 in Treg cells stood out.
To determine the stability of the protein expression patterns identified above, we performed a proteomic analysis after T cell expansion in vitro. nTreg and nTconv cells were expanded for 2 weeks in vitro by CD3, CD28, and IL-2 stimulation, rested for 4 days, and validated for their identity by FOXP3, Helios, CTLA-4, and CD25 staining and FOXP3 gene TSDR methylation ( Figures S4G-S4J) . Remarkably, the Treg cell-specific expression pattern of most of the proteins in the Treg cell core signature was largely conserved, even after re-activation via the CD3 and CD28 pathways ( Figures 4C, 4D , and S4K and Table S4 ). These findings suggest that the common Treg cell signature reflects core Treg cell properties, rather than their recent in vivo exposure to certain stimuli. We conclude that Treg cells intrinsically differ from Tconv cells in certain household and metabolic functions, as well as in the configuration of important signaling pathways. The eTreg lo cluster contained multiple GIMAPs that regulate apoptosis sensitivity (Figures 5A and 5B) . Importantly, almost 40% of the proteins in the eTreg lo cluster have functions in cellular signaling (Table S5) . They include multiple components of the NF-kB pathway (PRKCB, DPP4, NF-kB1, NF-kB2), cytokine receptor pathways (IL-7R, INPP4B, STAM2, STAT3), and the TCR pathway (TRAT1, VAV1, THEMIS). The fact that comparatively low expression was maintained for many of these proteins in Treg cells even after in vitro culture ( Figure S5A ) suggests that this apparent desensitization of signaling pathways is not just a reflection of negative feedback to activating signals via these pathways in vivo. FOXP3 physically interacts with key transcription factors and can quench their ability to transactivate Tconv cell effector genes, including IL17A and IL4 (Li and Zheng, 2015; Li et al., 2014; Rudra et al., 2012) . Vice versa, a factor such as YY1 can inhibit FOXP3-mediated control of the Treg cell program (Hwang et al., 2016) . To determine whether the relative concentration of FOXP3 in Treg cells is sufficient to ''overwhelm'' such interacting factors, we determined protein copy numbers per cell, using the proteomic ruler method (Wi sniewski et al., 2014) . We found that FOXP3 outnumbers many of its partner proteins in eTreg cells, with the greatest excess of FOXP3 over transcription factors such as NFATc1 and STAT4 ( Figure 5C ). For some transcription factors (YY1, RUNX1, and NFATc2), however, FOXP3 excess is only 2-to 3-fold, which may explain why even modest reduction in FOXP3 allows the production of effector cytokines by Treg cells (Wan and Flavell, 2007) . Finally, the results show that the expression level of FOXP3 in mTconv cells may be insufficient to effectively neutralize its partner transcription factors ( Figure 5C ).
eTreg Cells Exhibit Blunted Pathways Leading to Expression of Effector Genes
Ingenuity pathway analysis (IPA) highlighted adaptations in TCR, pattern recognition receptors (PRR), cytokine receptor, and TNFRSF family-induced NF-kB pathway signaling in eTreg as compared to Tconv cells ( Figure S5B ). Furthermore, protein but not mRNA levels of NF-kB1 (p50), NF-kB2 (p52), and RELA (p65) were lower in eTreg cells ( Figures S5C and S5D) , as confirmed by flow cytometry for NF-kB1 and NF-kB2 ( Figures  S5E-S5G) . Accordingly, anti-CD3-and anti-CD28-induced nuclear translocation of NF-kB1 was blunted in eTreg cells, but not in nTreg cells (Figures S5H and S5I ). NFATc1 and NFATc2 protein levels were lower in both nTreg cells and eTreg cells ( Figure S5J ). NFATc2, furthermore, appeared as low abundant in the common Treg cell signature and low expression of NFATc2 was maintained after Treg cell expansion in vitro (Figures 4A and  4D) . Finally, genes with NFATc2 binding elements in their promoters were underrepresented in the eTreg cell transcriptome ( Figure 6A ), suggesting that this factor is less active in these cells in vivo.
Inflammatory cytokines control critical aspects of Treg cell behavior but may challenge their stability Josefowicz et al., 2012; Tan et al., 2016; Yu et al., 2015) . Among STAT transcription factors, which relay cytokine receptor signals, STAT3, STAT6, and especially STAT4 exhibited low expression in eTreg cells. STAT4 expression was low both at the mRNA and protein level ( Figures S6A and S6B ) and low protein expression of STAT4 was part of the common Treg cell signature (Figure 4) . Genes with STAT4 binding elements in their promoters were also underrepresented in the eTreg cell transcriptome ( Figure 6A ), supporting the notion that STAT4 activity is reduced in eTreg cells in vivo. STAT4 is activated in human Figure S1B ) suggests that it is a mixed population containing cells resembling either Treg or Tconv cells. To better characterize this population, we separated it into two fractions based on CD127 expression. Proteomic analysis of each fraction was then performed and analyzed together with the proteomes of nTconv, mTconv, nTreg, and eTreg cells ( Figures S7A and S7B) . Hierarchical clustering and PCA showed that the CD127 + subpopulation was closely related to mTconv cells ( Figures 7A and 7B) , confirming the usefulness of CD127 to distinguish between Tconv and Treg cells. Remarkably, the CD127 À subpopulation was almost indistinguishable from eTreg cells. Only three proteins (LGAL10, PRG2, and FAU) were sufficiently differentially expressed between these two subsets to be identified as such (Table S6 ). The close proteomic relationship between CD127 À Fr.III and eTreg cells suggests that the former population may be a genuine Treg cell population. However, the TSDR in FOXP3 was much more methylated in CD127 À Fr.III cells than in eTreg cells ( Figure 7C ). Furthermore, CD127 À Fr.III cells contained a large proportion of cells that produced one or more effector cytokines ( Figure 7F , top row), unlike eTreg cells, which mostly lacked this ability. Not all cells in the CD127 À Fr.III population produced effector cytokines and not all cells in the eTreg cell population lacked the capacity to produce such cytokines, suggesting that even these better-defined populations might still be heterogeneous. We therefore searched for markers in our proteome dataset that Statistical analysis by two-way ANOVA followed by a Turkey's multiple comparison test (**p < 0.01; ***p < 0.001; indicate significant differences compared to the total population; #p < 0.05 indicate significant differences compared to CCR4 + CD49d À population).
might help distinguish between cells with different functional properties. Two markers, which have previously been found on Treg cells (Iellem et al., 2001; Kleinewietfeld et al., 2009 ), correlated positively (CD49d) or negatively (CCR4) with the relative ability of populations to produce effector cytokines ( Figures  7D, S7C, and S7D ). Flow cytometric analysis showed that these markers exhibit a mutually exclusive expression pattern (Figure 7E ) and identify cells with different functional properties within the eTreg cell and Fr.III populations. Those few cells in the eTreg cell population that produced IL-2 or IL-17 were most prominently found among cells expressing CD49d, consistent with an earlier report (Kleinewietfeld et al., 2009 S7F ). Our proteomic data thus led us to the discovery that CCR4 and CD49d distinguish cells with different abilities to produce effector cytokines within the eTreg cell and Fr.III populations. Combination of these markers with the commonly used panel of Treg cell markers may be useful for cell purification and diagnostic purposes. Their inclusion may, for instance, help clarify the association between the presence of FOXP3 + CD4 + T cells in tumors and patient prognosis, especially for cancers such as colon carcinoma, where this relationship has been tenuous (Saito et al., 2016) .
DISCUSSION
We identified proteomic signatures reflecting common Treg and eTreg cell-specific properties. These signatures comprised proteins involved in diverse cellular processes such as iron storage, lysosomal biogenesis, and transport, metabolism, cell signaling, and transcription. The composition of these signatures could not have been predicted on the basis of our own and earlier transcriptome analyses (Miyara et al., 2009; Schmidl et al., 2014) , but could be traced back in a recently published proteomic dataset covering human CD4 + T cell subsets (Rieckmann et al., 2017) .
Importantly, the relative expression pattern of the proteins in the common Treg cell signature and, to a lesser degree, the eTreg cell signature, was maintained after culture in vitro and even upon stimulation via CD3 and CD28. Therefore, our data are a robust resource to generate new hypotheses regarding human Treg cell biology, especially because the maintenance of the signatures in vitro provides an assay system to query their function.
Apart from identifying heterogeneity within Treg cell populations, our proteomic analysis sheds new light on mechanisms that help Treg cells protect their identity. Key in this identity are stable expression of FOXP3 and inability to produce effector cytokines. How and when Treg cells lose their identity is under debate (Sakaguchi et al., 2013) . They may be provoked to produce effector cytokines by chronic inflammation (Bailey- Bucktrout et al., 2013; Feng et al., 2014) , but this does not generally happen under acute inflammatory conditions, implying that barriers exist to prevent production of effector cytokines by Treg cells (Miyao et al., 2012; Rubtsov et al., 2010) . One such barrier involves inhibition by physical interaction of FOXP3 with transcription factors that promote Tconv effector cell gene expression (Rudra et al., 2012) . We found that FOXP3 is sufficiently abundant in eTreg cells to allow such a mechanism to operate. For some transcription factors, the difference in abundance was, however, no greater than 3-fold, such that even modest reduction in FOXP3 expression may dismantle this protective mechanism, consistent with experimental observations (Wan and Flavell, 2007) .
The Treg cell signatures reveal another barrier against production of effector cytokines: adjustments in signaling pathways downstream of CD3, CD28, TNFRSF, and cytokine receptors. These adjustments are most pronounced in eTreg cells, the cell type most likely to be exposed to inflammatory signals. Weak expression of proteins involved in CD3 and CD28 signaling is consistent with earlier findings that reduced TCR signaling capacity is critical for Treg cell stability in mice (Park et al., 2016; Yan et al., 2015) . Treg cells furthermore expressed high amounts of INPP5D (SHIP-1) and low amounts of RPS6KA1 and -3, suggesting desensitization of the AKTmTOR pathway, a key regulator of Tconv cell effector capacity (Chi, 2012) . Functional analyses have indeed indicated that this pathway is attenuated in Treg cells (Chi, 2012; Crellin et al., 2007) , although this finding is not unanimous (De Rosa et al., 2015; Procaccini et al., 2016) .
TNFa can destabilize Treg cells but can paradoxically also boost Treg cell expansion without compromising stability (Nie et al., 2013; Valencia et al., 2006; Zanin-Zhorov et al., 2010; Zaragoza et al., 2016) , suggesting that unknown elements may modify the response to this cytokine. We found that Treg cells exhibited adaptations in TNFR signaling, including weak expression of TNFR1 mRNA (the protein escaped detection) and its adaptor protein TRADD. On the other hand, these cells abundantly expressed TNFR2 mRNA and the OTULIN protein, an inhibitor of NF-kB downstream of TNFR1 and a suppressor of inflammatory disease (Damgaard et al., 2016) . It will be interesting to study whether modulation of these molecules underlies the different effects that TNFa can have on Treg cell stability (Nie et al., 2013; Valencia et al., 2006; Zanin-Zhorov et al., 2010; Zaragoza et al., 2016) .
Our data suggest that Treg cell identity may be insulated against destabilization by specific holes in its repertoire of transcription factors. For instance, several NF-kB pathway components were relatively weakly expressed. The role of NF-kB in Treg cells is complex. In mice, the NF-kB components c-Rel and p65 are required for thymic differentiation and maintenance of Treg cell identity, respectively (Grinberg-Bleyer et al., Oh et al., 2017) . However, unspecified NF-kB activity destabilized mature human Treg cells in response to TNFa (Nie et al., 2013; Valencia et al., 2006; Zanin-Zhorov et al., 2010) . Low abundance was most pronounced for (p105) NF-kB1 and (p100) NF-kB2 in eTreg cells. These molecules can act as activators and as repressors of NF-kB activity. It can therefore not be predicted whether their low expression inhibits or stimulates NF-kB activity or favors the formation of complexes lacking the p50 and p52 subunits derived from these precursors. Nonetheless, at least NF-kB1 recruits histone deacetylases to FoxP3 to inhibit its expression (Jana et al., 2009; Xiao et al., 2015) , suggesting that low expression of NF-kB1 helps to avoid loss of FOXP3 expression in Treg cells.
Several STAT transcription factors were weakly expressed in Treg cells. Low abundance of STAT4 protein was part of the common Treg cell signature and was reflected also in the Treg cell transcriptome. STAT4 is a major activator of IFNG in response to certain cytokines and antagonizes Treg cell development in mice (O'Shea and Plenge, 2012; Xu et al., 2011) . We here showed that forced expression of STAT4 in mature human Treg cells permitted type I IFN and IL-12 to provoke production of IFN-g. It also inhibited expression of FOXP3, perhaps through recruitment of methyl transferases to the CNS2 enhancer of FOXP3 . As STAT4 itself contains a binding site for FOXP3, both factors may have a mutually antagonistic relationship (STAT4 mRNA abundance was also low in Treg cells). Murine Treg cells weakly express the IL-12 receptor b2 chain to prevent IFN-g production (Koch et al., 2012) . In human T cells, both IL-12 and type I IFN can induce IFN-g production via STAT4 (Rogge et al., 1998) . Low abundance of this transcription factor therefore prevents induction of IFN-g production by either of these inflammatory cytokines. Having the cytokine receptors, but lacking STAT4, apparently allows Treg cells to respond to inflammatory cues (e.g., to instill homing properties) without compromising their identity. Perhaps, production of effector cytokines by Treg cells is useful under specific conditions and elevation of STAT4 expression may be one way to accomplish this. Indeed, expression of STAT4 was high in IFNg-producing ''fragile'' Treg cells, which are associated with relatively favorable prognosis in some tumors (Overacre-Delgoffe et al., 2017) .
Collectively, our proteomic measurements revealed specific core programs of human CD4 + Treg cell populations that will help increase the understanding of their function and perhaps enable their selective manipulation. The identification of surface markers that distinguish between bona fide Treg cells and CD4 + FOXP3 + T cells with the ability to produce inflammatory cytokines may furthermore help to select purer and more stable Treg cells for adoptive transfer therapies.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
CONTACT FOR REAGENT AND RESOURCE SHARING
Requests for resources and reagents and further information on protocols and experimental designs should be directed to and will be fulfilled by the Lead Contact, Derk Amsen (d.amsen@sanquin.nl).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Healthy blood donors Blood samples were obtained from anonymized healthy male donors with written informed consent in accordance to guidelines established by the Sanquin Medical Ethical Committee.
Cell Lines HEK293T cells were cultured in DMEM with HEPES (Life Technologies) supplemented with 10% FCS and 1% penicillin/streptomycin and maintained at 37 C degrees Celsius with 5% CO 2 .
METHOD DETAILS
Cell isolation and cell sorting Human PBMCs were isolated from fresh buffy coats from using Ficoll-Paque Plus (GE Healthcare) gradient centrifugation. Total CD4 + T cells were isolated using magnetic sorting with CD4 microbeads (Miltenyi Biotec) and viable cells were separated using flow cytometric sorting based on the expression of CD25, CD45RA, and CD127 on a FACS Aria III (BD Biosciences). Blood samples were obtained from anonymized healthy male donors with written informed consent in accordance to guidelines established by the Sanquin Medical Ethical Committee.
Antibodies
The following antibodies were used: CD25 (341011), CD45RA (560675), CD49d (559881), and CCR4 (557864) Sample preparation for mass spectrometry (MS) FACS-purified CD4 + subsets (at least 1x10 6 cells per subset) from 3-6 donors were placed in Protein LoBind tubes (Eppendorf), washed in PBS and lysed in 100 mM Tris HCl pH 8.0 with 4% SDS, 100 mM DTT. Samples were heated at 95 C, sonicated (Bioruptor) and after centrifugation (16,000 g), the supernatant cell lysates were isolated and stored at À80 C. Cell lysates were processed using filter aided sample preparation (FASP) as described (Wi sniewski et al., 2009) . Briefly, proteins were alkylated and digested into peptides using sequencing-grade Trypsin (Promega). Samples were desalted using StageTips (Rappsilber et al., 2003) , the aqueous phase was evaporated in a speedvac, and proteins were reconstituted in 2% acetonitrile in 0.1% TFA in water before analysis by MS.
Mass spectrometry data acquisition Tryptic peptides were separated by nanoscale C18 reverse chromatography coupled on line to an Orbitrap Fusion Tribrid mass spectrometer (Thermo Scientific) via a nanoelectrospray ion source (Nanospray Flex Ion Source, Thermo Scientific). Peptides were loaded on a 20 cm 75-360 mm inner-outer diameter fused silica emitter (New Objective) packed in-house with ReproSil-Pur C18-AQ, 1.9 mm resin (Dr Maisch GmbH). The column was installed on a Dionex Ultimate3000 RSLC nanoSystem (Thermo Scientific) using a MicroTee union formatted for 360 mm outer diameter columns (IDEX) and a liquid junction. The spray voltage was set to 2.15 kV. Buffer A was composed of 0.5% acetic acid and buffer B of 0.5% acetic acid, 80% acetonitrile. Peptides were loaded for 17 min at 300 nl/min at 5% buffer B, equilibrated for 5 minutes at 5% buffer B (17-22 min) and eluted by increasing buffer B from 5%-15% (22-87 min) and 15%-38% (87-147 min), followed by a 10 minute wash to 90% and a 5 min regeneration to 5%. Survey scans of peptide precursors from 400 to 1500 m/z were performed at 120K resolution (at 200 m/z) with a 1.5 3 10 5 ion count target. Tandem mass spectrometry was performed by isolation with the quadrupole with isolation window 1.6, HCD fragmentation with normalized collision energy of 30, and rapid scan mass spectrometry analysis in the ion trap. The MS 2 ion count target was set to 104 and the max injection time was 35 ms. Only those precursors with charge state 2-7 were sampled for MS 2 . The dynamic exclusion duration was set to 60 s with a 10 ppm tolerance around the selected precursor and its isotopes. Monoisotopic precursor selection was turned on. The instrument was run in top speed mode with 3 s cycles. All data were acquired with Xcalibur software.
Data Processing and Analysis
RAW mass spectrometry files were processed with the MaxQuant computational platform (Cox and Mann, 2008 ) version 1.5.2.8 using label-free quantitation (LFQ). Peptides were identified using the Andromeda search engine by querying the human Uniprot database 89796 entries) with a 1% false discovery rate (FDR) cut-off both at peptide and protein level. Potential contaminants and reverse hits were eliminated using Perseus version 1.5.0.31 (Cox and Mann, 2012) . To compare proteomes of different cell populations, LFQ values were log 2 -transformed and when appropriate the 3 technical replicates per experimental condition grouped. For further analysis, only proteins with 3 valid values in at least one of the groups were included. Missing values were imputed by normal distribution (width = 0.3, shift = 1.8). Intergroup differences in protein levels were calculated using either Kruskal-Wallis or ANOVA test followed by a Benjamini-Hochberg multiple testing correction with a 5% FDR. General relatedness of samples was assessed through Principal Component Analysis (PCA) using Perseus' built-in tool. Calculation of Pearson's correlations was assessed using Gitools (version 2.2.3)(Perez-Llamas and Lopez-Bigas, 2011). Clusters of proteins with specific expression patterns were identified using unsupervised hierarchical clustering based on K-means and Euclidian distance after z-score normalization. Cell type specific clusters were further analyzed for enrichment of functional and biological categories, using STRING and DAVID bioinformatics tools. Pathway diagrams were generated through the use of IngenuityÒ Pathway Analysis (IPAÒ, QIAGEN). GO biological processes redundancy was removed using REVIGO (Supek et al., 2011) . Absolute protein abundance was estimated using the proteomic ruler approach using a plug-in built in Perseus as described by the authors (Wi sniewski et al., 2014) . The abundances were expressed as protein copy numbers and the values were log 10 transformed and presented in graphs using Prism 6.0 (GraphPad Software, San Diego, CA, USA).
Gene set enrichment analysis was performed using the geneset collection C3 from the Molecular Signatures Database (MsigDB v4.0) that contains information about curated, motif, transcription factor target gene sets. The genes that share a transcription factor binding site are defined and annotated by TRANSFAC (Matys et al., 2006 ) (version 7.4).
RNA Isolation
Total RNA was extracted from 1 3 10 6 cells using TRIzol reagent (15596-018, Ambion Life Technologies) according to the manufacturer's protocol. The total RNA pellet was air-dried for 8 minutes and dissolved in an appropriate volume of nuclease free water (AM9937, Ambion Life Technologies) followed by a total RNA quantification using the Nanodrop UV-VIS Spectrophotometer (Thermo Scientific). The total RNA was further purified using the MinElute Cleanup Kit (74204, QIAGEN) according to the manufacturer's instructions. Quality and quantity of the total RNA was assessed by the 2100 Bioanalyzer using a Nano chip (Agilent, Santa Clara, CA). Total RNA samples having RNA Integrity Number (RIN)>8 were subjected to library generation.
TruSeq stranded mRNA sample preparation Strand-specific libraries were generated using the TruSeq Stranded mRNA sample preparation kit (ref. RS-122-2101/2, Illumina) according to the manufacturer's instructions. Briefly, polyadenylated RNA from intact total RNA was purified using oligo-dT beads. Following purification the RNA was fragmented, random primed and reverse transcribed using SuperScript II Reverse Transcriptase (18064-014, Invitrogen) with the addition of Actinomycin D. Second strand synthesis was performed using Polymerase I and RNaseH with replacement of dTTP for dUTP. The generated cDNA fragments were 3 0 end adenylated and ligated to Illumina Paired-end sequencing adapters and subsequently amplified by 12 cycles of PCR. The libraries were analyzed on a 2100 Bioanalyzer using a 7500 chip (Agilent), diluted and pooled equimolar into a 15-plex, 10 nM sequencing pool and stored at À20 C.
RNA-Seq data processing RNA-Seq raw reads Fastq were aligned to the Ensembl reference genome (Homo_sapiens.GRCh38.dna.primary_assembly) with TopHat (version 2.0.12, Bowtie version 1.0.0, Samtools version: 0.1.19). Read counts were generated by HTseq-count with uniquely mapped reads. Unmapped reads were discarded. Sequence reads were normalized to 10 million reads per sample and log2 transformed with the formula, log2(((expression gene 3 O library size)106)+1), where the library size was the sum of all expression values per sample. Read-counts were further analyzed by Qlucore Omics Explorer (3.1) for differential expression.
Protein and RNA comparison
The comparison of protein and transcript abundances across cell types was performed as published before (Wilhelm et al., 2014) . Briefly, absolute transcript abundances (expressed as fragment per kilobase per million, FPKM) were extracted from the RNASeq data. Absolute protein abundance was estimated using the intensity based absolute protein quantification (iBAQ) (Schwanh€ ausser et al., 2011 ) approach with few modifications described elsewhere (Wilhelm et al., 2014) . Briefly, peptide intensities were summed up and divided by the number of observable peptides per protein.
The iBAQ values were then normalized based on the total sum of all protein intensities in order to be able to compare abundances across samples. Proteins were mapped to transcripts using the Uniprot.ws package (Bioconductor) resulting in 4,792 transcripts/proteins with expression data. For the comparison of protein and mRNA abundances, protein and transcript expression of 409 differentially expressed proteins/RNAs was z-score-transformed. All the analyses were performed using R (v 3.2.0). ) were isolated by FACS sorting (FACS Aria III, BD Biosciences). The cells were then cultured in presence of 0.1 mg/ml of anti-CD3 mAb (M1654, clone 1XE, PeliCluster) and anti-CD28 mAb (16-0289-85, clone CD28.2, eBioscience) for 14 days in IMDM containing 10% FCS and 300 U/ml IL-2. The expanded cells were directly used for cytokine stimulation assays. For proteomics, the expanded cells were Cloning, lentivirus production and gene transduction The IRES-mCherry fragment of the pMSCV-IRES-mCherry vector was cloned into the lentiviral vector pCDH-EF1 linearized with EcoRI and SalI (pCDH-EF1 was a gift from Kazuhiro Oka -Addgene plasmid # 72266). The cDNA encoding STAT4 was PCR amplified from pLX304-STAT4-V5-mCherry using primers containing a 5 0 EcoRI and a 3 0 NotI restriction site. A C-terminal HA-tag was added to the reverse primer (fwd: 5 0 -TGGTGGTAGGGAATTCATGTCTCAGTGGAATCAAGT-3 0 and rev: 5 0 -CGTAGCGGCCGCTCAAGCG TAATCTGGAACATCGTATGGGTATTCAGCAGAATAAGGAG-3 0 ). The STAT4-HA cDNA was cloned into the EcoRI and SnaBI site of the pCDH-EF1-mCherry construct. All generated inserts were sequence verified. Lentivirus were produced as described previously by transfecting confluent HEK293T cells with packaging (psPAX2) and envelope plasmids (pMD2.G) with pCDH-EF1-mCherry or pCDH-EF1-STAT4-mCherry. HEK293T cells were cultured in DMEM with HEPES (Life Technologies) supplemented with 10% FCS and 1% penicillin/streptomycin. Polyethylenimine (Polysciences, Hirschberg an der Bergstrasse, Germany) was used as a transfection reagent. After 24 h, the cultures were refreshed with medium with 2% FCS and 24 h later, lentiviral particles were concentrated and purified by ultracentrifugation at 50,000 g for 2.5 h at 8 C. Freshly sorted nT convs and nT regs were expanded for 5 days as described above and restimulated one day prior to transduction. Cells were then transduced in RetroNectinÒ (Clontech) coated-plates for 24 h. After that, the cells were replated into tissue culture-treated plates with medium containing 100 U/ml IL-2 with or without IL-12 or IFNa. After 5 days the cells were stimulated with PMA/IO for 3 h.
In vitro cell expansion
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical tests, excluding those evaluating proteomic and RNaseq data, were performed using Prism 6.0 (GraphPad Software). All experiments were performed at least three independent times. The variable distribution was assessed by the Kolmogorov-Smirnov test. Nonparametric Kruskal-Wallis test was used followed by a Dunn's multiple comparison test to assess intergroup differences.
Two factor group differences were assessed using Row matched or normal Two-way ANOVA followed by Tukey's or Bonferroni's multiple comparison test. A p < 0.05 was considered statistically significant at a 95% confidence level. Data are presented as mean ± SEM unless otherwise indicated in figure legends. Significance levels are: * p < 0.05; ** p < 0.01; *** p < 0.001.
DATA AND SOFTWARE AVAILABILITY
The mass spectrometry data have been deposited to the ProteomeXchange Consortium (http://proteomecentral.proteomexchange. org) via the PRIDE (Vizcaíno et al., 2016) repository with the dataset identifier PDX007745, PDX007744, and PXD005477. RNASeq data can be accessed with accession number GSE90600.
